Press release
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics,
DelveInsight's, "Myelodysplastic Syndrome - Pipeline Insight, 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.DelveInsight reports that the Myelodysplastic Syndrome (MDS) pipeline includes over 120 key companies actively developing more than 125 therapeutic candidates.
Myelodysplastic Syndrome Overview:
Myelodysplastic syndrome (MDS) is a heterogeneous group of blood cancers characterized by clonal disorders of hematopoietic stem cells, leading to abnormal cell development (dysplasia) and ineffective blood cell production in the bone marrow. In some cases, MDS can progress to acute myeloid leukemia (AML). It is most commonly diagnosed in individuals over 65 and is associated with reduced levels of red blood cells, white blood cells, and platelets. The severity and symptoms of MDS can vary widely among patients.
The condition can arise from multiple factors, including environmental exposures such as benzene or radiation, prior chemotherapy, or idiopathic causes, particularly in older adults. Certain inherited or acquired bone marrow failure syndromes, like Fanconi anemia and acquired aplastic anemia, may increase the risk of MDS or mimic its features.
MDS can occur spontaneously (de novo) or as a result of other conditions or treatments, referred to as treatment-related MDS. Use of drugs such as alkylating agents or topoisomerase II inhibitors has been linked to MDS, typically developing 2 to 7 years post-treatment. The disease often involves genetic and chromosomal abnormalities, either present initially or arising from these risk factors. Over 80% of patients exhibit such abnormalities, which may include chromosome translocations or aneuploidy (chromosomal gains or losses).
Download our report @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Myelodysplastic Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
*
DelveInsight's report on the Myelodysplastic Syndrome (MDS) pipeline highlights a dynamic landscape, with over 120 companies actively developing more than 125 therapeutic candidates.
*
In June 2024, the FDA approved imetelstat (Rytelo) for adults with low- to intermediate-1 risk MDS who have transfusion-dependent anemia requiring four or more red blood cell units over eight weeks and who have not responded to, or are ineligible for, erythropoiesis-stimulating agents.
*
Leading companies advancing MDS treatments include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
*
Notable MDS pipeline therapies in development include Tamibarotene, CA-4948, RVU120, MNV-201, among several additional candidates.
Myelodysplastic Syndrome Pipeline Analysis
The Myelodysplastic Syndrome pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Myelodysplastic Syndrome Market.
*
Categorizes Myelodysplastic Syndrome therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Myelodysplastic Syndrome drugs under development based on:
*
Stage of development
*
Myelodysplastic Syndrome Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Myelodysplastic Syndrome Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Myelodysplastic Syndrome Licensing agreements
*
Funding and investment activities supporting future Myelodysplastic Syndrome market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Myelodysplastic Syndrome Emerging Drugs
*
Tamibarotene: Syros Pharmaceuticals
*
CA-4948: Curis
*
RVU120: Ryvu Therapeutics
*
MNV-201: Minovia Therapeutics
Myelodysplastic Syndrome Companies
More than 120 leading companies are actively developing therapies for Myelodysplastic Syndrome (MDS), with Syros Pharmaceuticals advancing a drug candidate to the most advanced stage, Phase III clinical trials.
DelveInsight's report covers around 125+ products under different phases of Myelodysplastic Syndrome clinical trials like
*
Myelodysplastic Syndrome Late stage Therapies (Phase III)
*
Myelodysplastic Syndrome Mid-stage Therapies (Phase II)
*
Myelodysplastic Syndrome Early-stage Therapies (Phase I)
*
Myelodysplastic Syndrome Pre-clinical and Myelodysplastic Syndrome Discovery stage Therapies
*
Myelodysplastic Syndrome Discontinued & Inactive Therapies
Myelodysplastic Syndrome pipeline report provides the Myelodysplastic Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Myelodysplastic Syndrome Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Myelodysplastic Syndrome Therapies and Key Myelodysplastic Syndrome Companies: Myelodysplastic Syndrome Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Myelodysplastic Syndrome Pipeline Therapeutic Assessment
- Myelodysplastic Syndrome Assessment by Product Type
- Myelodysplastic Syndrome By Stage
- Myelodysplastic Syndrome Assessment by Route of Administration
- Myelodysplastic Syndrome Assessment by Molecule Type
Download Myelodysplastic Syndrome Sample report to know in detail about the Myelodysplastic Syndrome treatment market @ Myelodysplastic Syndrome Therapeutic Assessment [https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Myelodysplastic Syndrome Current Treatment Patterns
4. Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)
7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myelodysplastic Syndrome Discontinued Products
13. Myelodysplastic Syndrome Product Profiles
14. Myelodysplastic Syndrome Key Companies
15. Myelodysplastic Syndrome Key Products
16. Dormant and Discontinued Products
17. Myelodysplastic Syndrome Unmet Needs
18. Myelodysplastic Syndrome Future Perspectives
19. Myelodysplastic Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Myelodysplastic Syndrome Pipeline Reports Offerings [https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myelodysplastic-syndrome-pipeline-analysis-2025-by-delveinsight-novartis-syros-pharmaceuticals-curis-ryvu-therapeutics-chia-tai-tianqing-pharmaceutical-group-amgen-sanofi-forma-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, here
News-ID: 4165686 • Views: …
More Releases from ABNewswire

The Great Unroboting: AI-Text-Humanizer.com Improves the Human-AI Collaboration …
MUNICH, GERMANY - September 30, 2025 - As companies hurry to integrate Artificial Intelligence into their workflows, a critical challenge emerged: The loss of the human touch. From sales emails to internal memos - AI-generated communication is often generic, impersonal but also ineffective. AI-Text-Humanizer.com started its enterprise platform to solve this problem - to improve human-AI collaboration.
The drive for AI-powered efficiency has created a corporate communications crisis. Sales outreach emails…

Phenix City Medical Practice Announces Expanded Healthcare Services, Addressing …
Preferred Medical Group, Phenix City, announces the expansion of its healthcare services and improved patient access, addressing community demand for comprehensive medical care with integrated pediatric, adult, and therapeutic services under one roof.
Preferred Medical Group, Phenix City [https://preferredmedgroup.com/], has announced significant enhancements to its healthcare services, responding to increased community demand for accessible and comprehensive medical care. The medical practice, located at 3700 South Railroad Street, has introduced streamlined patient…

Auburn Medical Practice Expands Integrated Care Model as Primary Care Doctor Add …
Preferred Medical Group - Auburn expands ADHD services and integrated care model, offering comprehensive family medicine, behavioral health, and specialized attention disorder treatment in one convenient East Alabama location.
Preferred Medical Group - Auburn [https://preferredmedgroup.com/] has announced significant enhancements to its integrated healthcare services, responding to increased demand for ADHD treatment and comprehensive family medical care in East Alabama. The Auburn location, situated at 318 Samford Village Court, Suite 100, now…

Local ADHD Doctor Program Launches at Preferred Medical Group - Opelika for East …
Preferred Medical Group - Opelika launches an integrated ADHD treatment program that combines pediatric care, psychiatry, and therapy services to address regional healthcare needs for East Alabama families.
Opelika healthcare providers have taken a significant step toward addressing the growing need for specialized attention deficit hyperactivity disorder services in East Alabama. Preferred Medical Group - Opelika [https://preferredmedgroup.com/] has announced the expansion of comprehensive ADHD treatment programs, integrating pediatric care with behavioral…
More Releases for Myelodysplastic
Myelodysplastic Syndrome Drugs Market Research and Treatment Advancements
On April 11, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Myelodysplastic Syndrome Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands…
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.
The myelodysplastic syndrome (MDS)…
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders…
Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic…
Myelodysplastic Syndrome Market Size, Epidemiology, Analysis & Trends 2023-2033
Market Overview:
The myelodysplastic syndrome market is expected to exhibit a CAGR of 6.51% during 2023-2033. The myelodysplastic syndrome market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Myelodysplastic Syndrome Market to see Huge Growth by 2029
Myelodysplastic Syndrome Market was valued at USD 2.8 billion in 2022 and is expected to grow at a CAGR of 10% between 2023 and 2029. Important changes in the business allow key players to attain larger profits. This Myelodysplastic Syndrome Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry.…